All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

TAR-200 Yields Prolonged DFS in BCG-Unresponsive, Papillary High-Risk NMIBC

April 26th 2025

TAR-200 produced durable disease-free survival in BCG-unresponsive, papillary-only, high-risk non–muscle-invasive bladder cancer.

Sasanlimab Plus BCG Improves EFS in High-Risk NMIBC

April 26th 2025

Sasanlimab plus BCG significantly improved EFS vs BCG alone in high-risk non–muscle-invasive bladder cancer.

MRD Assessment Informs RFS Outcomes With Cretostimogene Grenadenorepvec in BCG-Unresponsive NMIBC

April 26th 2025

Twelve-month RFS was associated with MRD status in patients with BCG-unresponsive, NMIBC who received treatment with cretostimogene grenadenorepvec.

UGN-301 Shows Early Tolerability in Recurrent Non–Muscle-Invasive Bladder Cancer

April 26th 2025

Continued evaluation of UGN-301 in patients with recurrent NMIBC is warranted.

The OncFive: Top Oncology Articles for the Week of 4/20

April 26th 2025

Penpulimab gets green light from FDA for nasopharyngeal carcinoma, sacituzumab govitecan combination boosts PFS in TNBC, and more.

Oncology Experts Preview Abstracts to Watch at the 2025 AACR Annual Meeting

April 25th 2025

Experts from across oncology specialties highlight research being presented at the 2025 AACR Annual Meeting.

AI in Cancer Care, Targeted Therapies Among Cancer Conference Talks

April 25th 2025

UCSF experts highlight leadership in innovative cancer research and education.

CHMP Recommends EU Approval of Zanidatamab for HER2+ Advanced Biliary Tract Cancer

April 25th 2025

The EMA’s CHMP issued a positive opinion for zanidatamab in previously treated HER2-positive biliary tract cancer.

CHMP Recommends Brentuximab Vedotin Plus ECADD for Newly Diagnosed Stage IIB/III/IV Hodgkin Lymphoma

April 25th 2025

The EMA’s CHMP has recommended the approval of brentuximab vedotin plus ECADD for newly diagnosed, stage IIB/III/IV Hodgkin lymphoma.

Orelabrutinib Wins Approval in China for First-Line CLL and SLL

April 25th 2025

China’s NMPA has approved orelabrutinib for the first-line treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma.

FDA Approval of Cabozantinib for Pancreatic and Extra-Pancreatic Neuroendocrine Tumors Opens the Door to a New Standard Option

April 25th 2025

Jennifer Chan, MD, MPH, highlights the significance of the FDA approval of cabozantinib for the treatment of patients with pNET and epNET.

China’s NMPA Approves Toripalimab in First-Line Melanoma

April 25th 2025

China’s NMPA has approved the sNDA for toripalimab as a first-line treatment for patients with unresectable or metastatic melanoma.

Awareness Efforts Aim to Drive Earlier Esophageal Cancer Detection Amid Rising Incidence Rates

April 25th 2025

Nataliya Uboha, MD, PhD, highlights the importance of standard endoscopic procedures for the early detection of esophageal cancer.

Rina-S Displays Early Efficacy in Advanced Ovarian Cancer

April 25th 2025

Elizabeth K. Lee, MD, discusses data from the phase 1/2 RAINFOL-01 study of Rina-S in advanced ovarian cancer.

Meta Analysis Shows Efficacy Trend Favoring Zanubrutinib in High-Risk R/R CLL

April 24th 2025

A network meta analysis compared the efficacy of BTK inhibitors in patients with high-risk R/R chronic lymphocytic leukemia.

Mirdametinib Use in NF1-Associated PNs Balances Efficacy and QOL Considerations

April 24th 2025

Rene Y. McNall-Knapp, MD, discusses the symptom management associated with mirdametinib and MEK inhibition in NF1-associated PNs.

Roswell Park Researchers to Discuss Recent Discoveries and Critical Issues in Oncology at AACR 2025

April 24th 2025

Researchers from Roswell Park Comprehensive Cancer Center will report their latest findings to colleagues at the 2025 AACR Annual Meeting.

Japanese Approval Is Sought for T-DXd in HER2+ Advanced Solid Tumors

April 24th 2025

Japan’s Ministry of Health has received a supplemental new drug application for T-DXd for HER2-positive advanced or recurrent solid tumors.

Optune Lua Granted CE Mark Approval in EU for Metastatic NSCLC

April 24th 2025

A CE Mark has been granted to Optune Lua concurrent with immune checkpoint inhibitors or docetaxel for patients with metastatic non–small cell lung cancer.

FDA Approves Penpulimab for Non-Keratinizing Nasopharyngeal Carcinoma

April 24th 2025

The FDA has approved penpulimab for select patients with non-keratinizing nasopharyngeal carcinoma.